Site-directed Recombination Via Bifunctional PNA-DNA Conjugates
Overview
Affiliations
Site-specific DNA binding molecules offer the potential for genetic manipulation of mammalian cells. Peptide nucleic acids (PNAs) are a DNA mimic in which the purine and pyrimidine bases are attached to a polyamide backbone. PNAs bind with high affinity to single-stranded DNA via Watson-Crick base pairing and can form triple helices via Hoogsteen binding to DNAPNA duplexes. Dimeric bis-PNAs capable of both strand invasion and triplex formation can form clamp structures on target DNAs. As a strategy to promote site-directed recombination, a bis-PNA was coupled to a 40-nt donor DNA fragment homologous to an adjacent region in the target gene. The PNA-DNA conjugate was found to mediate site-directed recombination with a plasmid substrate in human cell-free extracts, resulting in correction of a mutation in a reporter gene at a frequency at least 60-fold above background. Induced site-specific recombination was also seen when the bis-PNA and the donor DNA were co-mixed without covalent linkage. In addition, the bis-PNA and the bis-PNA-DNA conjugate were found to induce DNA repair specifically in the target plasmid. Both the PNA-induced recombination and the PNA-induced repair were found to be dependent on the nucleotide excision repair factor, XPA (xeroderma pigmentosum complementation group A protein). These results suggest that the formation of a PNA clamp on duplex DNA creates a helical distortion that strongly provokes DNA repair and thereby sensitizes the target site to recombination. The ability to promote recombination in a site-directed manner using PNA-DNA conjugates may provide a useful strategy to achieve targeted correction of defective genes.
Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation.
Gupta A, Barone C, Quijano E, Piotrowski-Daspit A, Perera J, Riccardi A J Cyst Fibros. 2024; 24(1):142-148.
PMID: 39107154 PMC: 11788067. DOI: 10.1016/j.jcf.2024.07.009.
Falanga A, Lupia A, Tripodi L, Morgillo C, Moraca F, Roviello G Heliyon. 2024; 10(3):e24599.
PMID: 38317891 PMC: 10839560. DOI: 10.1016/j.heliyon.2024.e24599.
Oyaghire S, Quijano E, Perera J, Mandl H, Saltzman W, Bahal R Cell Rep Phys Sci. 2023; 4(10).
PMID: 37920723 PMC: 10621889. DOI: 10.1016/j.xcrp.2023.101635.
Mikame Y, Yamayoshi A Pharmaceutics. 2023; 15(10).
PMID: 37896275 PMC: 10609763. DOI: 10.3390/pharmaceutics15102515.
Nanoparticle delivery of TFOs is a novel targeted therapy for HER2 amplified breast cancer.
Yang X, Xu Y, Fu J, Shen Z BMC Cancer. 2023; 23(1):680.
PMID: 37468837 PMC: 10357592. DOI: 10.1186/s12885-023-11176-8.